Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 2
1957 2
1959 1
1960 1
1962 6
1963 4
1964 15
1965 9
1966 9
1967 8
1968 7
1969 16
1970 9
1971 8
1972 9
1973 7
1974 6
1975 6
1976 4
1977 6
1978 11
1979 12
1980 16
1981 24
1982 25
1983 27
1984 24
1985 24
1986 17
1987 26
1988 22
1989 32
1990 27
1991 26
1992 23
1993 23
1994 26
1995 28
1996 26
1997 37
1998 36
1999 37
2000 17
2001 34
2002 50
2003 30
2004 48
2005 40
2006 36
2007 36
2008 52
2009 51
2010 58
2011 75
2012 116
2013 137
2014 135
2015 104
2016 105
2017 105
2018 119
2019 126
2020 152
2021 162
2022 156
2023 153
2024 58

Text availability

Article attribute

Article type

Publication date

Search Results

2,580 results

Results by year

Filters applied: . Clear all
Page 1
Primary stroke prevention worldwide: translating evidence into action.
Owolabi MO, Thrift AG, Mahal A, Ishida M, Martins S, Johnson WD, Pandian J, Abd-Allah F, Yaria J, Phan HT, Roth G, Gall SL, Beare R, Phan TG, Mikulik R, Akinyemi RO, Norrving B, Brainin M, Feigin VL; Stroke Experts Collaboration Group. Owolabi MO, et al. Among authors: ishida m. Lancet Public Health. 2022 Jan;7(1):e74-e85. doi: 10.1016/S2468-2667(21)00230-9. Epub 2021 Oct 29. Lancet Public Health. 2022. PMID: 34756176 Free PMC article. Review.
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Ishida M, Katayama Y, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K. Kawachi H, et al. Among authors: ishida m. JAMA Netw Open. 2023 Jul 3;6(7):e2322915. doi: 10.1001/jamanetworkopen.2023.22915. JAMA Netw Open. 2023. PMID: 37432682 Free PMC article.
Architecture of the ESCPE-1 membrane coat.
Lopez-Robles C, Scaramuzza S, Astorga-Simon EN, Ishida M, Williamson CD, Baños-Mateos S, Gil-Carton D, Romero-Durana M, Vidaurrazaga A, Fernandez-Recio J, Rojas AL, Bonifacino JS, Castaño-Díez D, Hierro A. Lopez-Robles C, et al. Among authors: ishida m. Nat Struct Mol Biol. 2023 Jul;30(7):958-969. doi: 10.1038/s41594-023-01014-7. Epub 2023 Jun 15. Nat Struct Mol Biol. 2023. PMID: 37322239 Free PMC article.
A new face among our Associate Editors.
Ishida M. Ishida M. Hypertens Res. 2023 May;46(5):1207-1209. doi: 10.1038/s41440-023-01247-5. Epub 2023 Mar 8. Hypertens Res. 2023. PMID: 36890268 No abstract available.
Cigarette Smoking and Atherosclerotic Cardiovascular Disease.
Ishida M, Sakai C, Kobayashi Y, Ishida T. Ishida M, et al. J Atheroscler Thromb. 2024 Mar 1;31(3):189-200. doi: 10.5551/jat.RV22015. Epub 2024 Jan 14. J Atheroscler Thromb. 2024. PMID: 38220184 Free PMC article. Review.
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
Komura K, Hirosuna K, Tokushige S, Tsujino T, Nishimura K, Ishida M, Hayashi T, Ura A, Ohno T, Yamazaki S, Nakamori K, Kinoshita S, Maenosono R, Ajiro M, Yoshikawa Y, Takai T, Tsutsumi T, Taniguchi K, Tanaka T, Takahara K, Konuma T, Inamoto T, Hirose Y, Ono F, Shiraishi Y, Yoshimi A, Azuma H. Komura K, et al. Among authors: ishida m. Mol Cancer. 2023 Nov 18;22(1):185. doi: 10.1186/s12943-023-01897-6. Mol Cancer. 2023. PMID: 37980528 Free PMC article.
A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity.
Yazawa R, Ishida M, Balavarca Y, Hennige AM. Yazawa R, et al. Among authors: ishida m. Diabetes Obes Metab. 2023 Jul;25(7):1973-1984. doi: 10.1111/dom.15064. Epub 2023 Apr 27. Diabetes Obes Metab. 2023. PMID: 36974349 Clinical Trial.
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer.
Katayama Y, Yamada T, Tanimura K, Tokuda S, Morimoto K, Hirai S, Matsui Y, Nakamura R, Ishida M, Kawachi H, Yoneda K, Hosoya K, Tsuji T, Ozasa H, Yoshimura A, Iwasaku M, Kim YH, Horinaka M, Sakai T, Utsumi T, Shiotsu S, Takeda T, Katayama R, Takayama K. Katayama Y, et al. Among authors: ishida m. NPJ Precis Oncol. 2023 Jan 26;7(1):12. doi: 10.1038/s41698-023-00350-7. NPJ Precis Oncol. 2023. PMID: 36702855 Free PMC article.
Akathisia, an Easily Overlooked Side Effect.
Onishi H, Yoshioka A, Sato I, Uchida N, Ishida M. Onishi H, et al. Among authors: ishida m. J Clin Oncol. 2023 Sep 1;41(25):4184-4185. doi: 10.1200/JCO.23.00853. Epub 2023 Jun 23. J Clin Oncol. 2023. PMID: 37352484 No abstract available.
2,580 results